PubRank

John A Thompson

Author PubWeight™ 138.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 19.58
2 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 13.52
3 Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008 7.80
4 Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010 7.25
5 A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009 5.99
6 Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009 4.58
7 Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012 3.65
8 Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002 3.05
9 Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004 2.37
10 Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 2007 2.19
11 An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004 2.18
12 A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 2014 2.05
13 Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011 1.78
14 Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012 1.58
15 Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 2009 1.51
16 The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013 1.46
17 Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013 1.44
18 Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004 1.42
19 Melanoma. J Natl Compr Canc Netw 2009 1.37
20 Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem 2005 1.36
21 New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003 1.34
22 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010 1.30
23 A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006 1.25
24 Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004 1.25
25 Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 2005 1.22
26 Mitochondrial targets of oxidative stress during renal ischemia/reperfusion. Arch Biochem Biophys 2003 1.21
27 C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res 2008 1.20
28 Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010 1.19
29 Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002 1.15
30 Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2009 1.15
31 Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis 2006 1.13
32 Melanoma, version 4.2014. J Natl Compr Canc Netw 2014 1.07
33 Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002 1.06
34 Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 2002 1.05
35 Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 2002 1.03
36 Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016 1.02
37 Immunochemical and proteomic analysis of covalent adducts formed by quinone methide tumor promoters in mouse lung epithelial cell lines. Chem Res Toxicol 2005 1.02
38 Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009 1.01
39 Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis 2007 0.99
40 Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother 2008 0.98
41 A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol 2010 0.96
42 Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs 2015 0.96
43 Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006 0.95
44 A statistical method for quantifying songbird phonology and syntax. J Neurosci Methods 2008 0.95
45 Influence of gallate esterification on the activity of procyanidin B2 in androgen-dependent human prostate carcinoma LNCaP cells. Pharm Res 2010 0.91
46 Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009 0.90
47 Melanoma. J Natl Compr Canc Netw 2012 0.90
48 Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014 0.90
49 Enhanced rat islet function and survival in vitro using a biomimetic self-assembled nanomatrix gel. Tissue Eng Part A 2010 0.89
50 Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther 2009 0.87
51 Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 2008 0.86
52 Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes. Chem Res Toxicol 2007 0.86
53 Fibroblast growth factor mediates hypoxia-induced endothelin-- a receptor expression in lung artery smooth muscle cells. J Appl Physiol (1985) 2003 0.85
54 Inhibition of glutathione S-transferase P1-1 in mouse lung epithelial cells by the tumor promoter 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone (BHT-quinone methide): protein adducts investigated by electrospray mass spectrometry. Chem Res Toxicol 2004 0.85
55 Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES. Arch Biochem Biophys 2006 0.84
56 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 2011 0.83
57 Melanoma. J Natl Compr Canc Netw 2006 0.83
58 A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs 2006 0.83
59 Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Canc Netw 2012 0.83
60 Procyanidin B2 3,3(″)-di-O-gallate, a biologically active constituent of grape seed extract, induces apoptosis in human prostate cancer cells via targeting NF-κB, Stat3, and AP1 transcription factors. Nutr Cancer 2013 0.82
61 Sodium nitrite protects against kidney injury induced by brain death and improves post-transplant function. Kidney Int 2012 0.82
62 Effects of venous needle turbulence during ex vivo hemodialysis on endothelial morphology and nitric oxide formation. J Biomech 2006 0.82
63 Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010 0.81
64 Systemic therapy of metastatic melanoma: on the road to cure. Oncology (Williston Park) 2015 0.81
65 Antibacterial properties of an iron-based hemostatic agent in vitro and in a rat wound model. Acad Emerg Med 2009 0.80
66 Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013 0.80
67 Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 2007 0.79
68 Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4-methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity. Chem Res Toxicol 2002 0.79
69 Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy. J Gastrointest Surg 2002 0.79
70 Peroxynitrite modulates acidic fibroblast growth factor (FGF-1) activity. Arch Biochem Biophys 2003 0.78
71 Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw 2005 0.78
72 Glucuronidation and methylation of procyanidin dimers b2 and 3,3″-di-o-galloyl-b2 and corresponding monomers epicatechin and 3-o-galloyl-epicatechin in mouse liver. Pharm Res 2011 0.78
73 Protein damage from electrophiles and oxidants in lungs of mice chronically exposed to the tumor promoter butylated hydroxytoluene. Chem Biol Interact 2011 0.77
74 Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther 2011 0.77
75 Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002 0.77
76 Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene. Chem Biol Interact 2003 0.77
77 The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 2005 0.77
78 Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite. Arch Biochem Biophys 2003 0.77
79 Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck 2014 0.77
80 Carbonyl reductase inactivation may contribute to mouse lung tumor promotion by electrophilic metabolites of butylated hydroxytoluene: protein alkylation in vivo and in vitro. Chem Res Toxicol 2008 0.76
81 Glomerular targeting of acidic fibroblast growth factor-1 in renal transplanted rats. Transplantation 2002 0.75
82 Optic Radiation Tractography and Visual Field Deficits in Laser Interstitial Thermal Therapy for Amygdalohippocampectomy in Patients with Mesial Temporal Lobe Epilepsy. Stereotact Funct Neurosurg 2017 0.75